Shilpa Medicare’s arm completes Human Clinical studies of High concentration Biosimilar Adalimumab

19 Aug 2022 Evaluate

Shilpa Medicare via its wholly owned subsidiary, Shilpa Biologicals (SBPL), has successfully completed the phase 3 Human Clinical studies of its first biosimilar, the 100mg/ml High Concentration (HC) Adalimumab biosimilar and has submitted the dossier to the CDSCO for review and grant of marketing/manufacturing license - a first in India.

The drug is expected to cater to the fast growing Rheumatoid Arthritis, Plaque Psoriasis, JIA, Psoriatic Arthritis, Ankylosing Spondylitis, Ulcerative Colitis, Crohns disease, HS and Uveitis markets - diseases where India has the largest patient populations.

Shilpa Medicare produces and exports consistently high-quality Active Pharmaceutical Ingredients Fine Chemicals, intermediates, herbal products and speciality chemical products using sophisticated technology, meticulously following international specifications.

Shilpa Medicare Share Price

321.10 -0.10 (-0.03%)
01-Jan-2026 10:11 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1713.60
Dr. Reddys Lab 1255.15
Cipla 1504.35
Zydus Lifesciences 909.90
Lupin 2086.40
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×